FREE Account Opening + No Clearing Fees

Narayana Hrudayalaya Ltd IPO Review (Apply)

Review By Dilip Davda on December 12, 2015

NHL was founded in 2000 by Promoter, Dr. Devi Prasad Shetty, who has over 30 years of medical experience, including as a cardiac surgeon, the Company is one of the leading private healthcare service providers in India, operating a chain of multispecialty, tertiary and primary healthcare facilities. As of the date of the Red Herring Prospectus, it had a network of 23 hospitals (multispecialty and superspeciality healthcare facilities which provide tertiary care), 8 heart centres (superspeciality units which are set up in a third party hospital) and 24 primary care facilities (including clinics and information centres), across a total of 31 cities, towns and villages in India, with 5,442 operational beds and the potential to reach a capacity of up to 6,602 beds. In FY 2015, the facilities provided care to over 1.97 million patients. Headquartered in Bengaluru, it operates a national network of hospitals in India with a particularly strong presence in the southern state of Karnataka and eastern India, as well as an emerging presence in western and central India. As of September 30, 2015, it had 11,163 employees, which included 344 doctors, 5,587 nurses, 1,996 paramedical staff and 3,236 administrative personnel. Additionally, it had 487 students, which included 469 doctors, 14 paramedics and 4 administrative trainees. Further, it had 1,750 doctors on a consultancy basis (including visiting consultants) engaged in the system. NHL believes in bringing affordable healthcare services to the masses of India in particular and the global masses in general. NHL has four healthcare projects underway at Vaishnodevi, Lucknow, Bhuwaneshwar and Mumbai and all these are expected to be on stream in next 12 to 24 months. These projects will add around 1000 beds on completion. Most of the projects are on PPP model thus it reduces capex for NHL.

For unlocking the value for stakeholders and listing of its equity, the company is planning a maiden IPO via secondary route i.e. offer for sale by existing shareholders who are offering on an aggregate 24523297 equity shares of Rs. 10 each via book building route in a price band of Rs. 245-250.  Minimum application is to be made for 60 shares and in multiples thereon, thereafter. Issue opens for subscription for Anchor Investors on 16.12.15 and for others; the issue will remain open from 17.12.15 to 21.12.15. This offer will constitute around 12% of the post issue paid up capital of the company. BRLMs to this offer are Axis Capital Ltd, IDFC Securities Ltd and Jefferies India Pvt Ltd and Karvy Computershare Pvt Ltd is the registrar to the issue. Post allotment shares will be listed on BSE and NSE. With this offer, seller stakeholders will realize around Rs. 613 crore at the upper price band.  As this being an offer for sale, no funds are coming to the company. Discount to retail investors that was planned while filing DRHP is missing.

The company having issued initial capital at par during 2000 and 2001 and then issued 75414 equity share of Rs. 10 each at a price of Rs. 53040.55 per share in February 2008 and 20339 shares at a price of Rs. 98336.27 in December 2014. It also issued bonus in the ratio of 577.45 shares for every 1 share held in March 2015 and then converted OCDs into 4360804 equity shares at a price of Rs. 244.67 per share in December 2015. Its current paid up equity is at Rs. 204.36 crore.

On performance front, the company has posted an average EPS of Rs. 0.50 (on consolidated basis) and Rs. 1.56 (on standalone basis) for last three fiscals. In fact for the fiscal 2015 it reported loss and thus its RoNW turned negative. For the fiscal 2015 it has posted loss of Rs. 10.86 crore on a turnover of Rs. 1371.58 crore. For last four fiscals it has reported CAGR of 30% in total revenues and 23.80% in EBITDA. For the first half of current fiscal, it has posted net profit of Rs.  12.49 crore on a turnover of Rs.788.56 crore (on consolidated basis). If we annualize these and attribute to the existing equity capital of Rs. 204.36 crore, the EPS will be around Rs. 1.22 and thus the issue is at a P/E of around 200 plus. Its peers (although not comparable on strict norms and business model of NHL) trading at a P/E of around (55) Apollo Hospital, (17) Fortis Malar, (23) Kovai Medical etc. The basic difference between all peers and NHL is the business mix. While others have Premium verses General ratio of 75:25, NHL has the reverse one i.e. 25:75 as it believes in growth via volumes at affordable pricing and is the most preferred partner for many NGOs for the said cause.

According to market sources, this IPO is generating fancy despite being aggressively priced as it is the first mover in business model (affordable world class healthcare services) and may have re-run of IndiGo. IPO pricing largely discounts near term prospects but has bright prospects ahead once it’s all plans are afoot.

Conclusion / Investment Strategy

Although IPO pricing is the main concern, hype created by business model and rising fancy makes this offer a worthy bet for short to long term.

Reviewer recommends Subscribing to the issue.

Review By Dilip Davda on December 12, 2015

Review Author

DISCLAIMER: No financial information whatsoever published anywhere here should be construed as an offer to buy or sell securities, or as advice to do so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions. Readers must consult a qualified financial advisor before making any actual investment decisions, based on the information published here. My reviews do not cover GMP market and operators game plans. Any reader taking decisions based on any information published here does so entirely at their own risk. Investors should bear in mind that any investment in stock markets is subject to unpredictable market-related risks. The above information is based on RHP and other documents available as of date coupled with market perception. The author has no plans to invest in this offer.

About Dilip Davda

Dilip Davda, a freelance journalist

Dilip Davda is veteran journalist associated with stock market since 1978. He is contributing to print and electronic media on stock markets/insurance/finance since 1985.

Dilip Davda is a leading reviewer of public issues and NCDs in the primary stock market in India. The knowledge he gained over 3 decades while working in the stock market and a strong relationship with popular lead managers makes his reviews unique. His detail fundamental and financial analysis of companies coming up with IPO helps investors in the primary stock market. Dilip Davda has a special interest in analyzing the SME companies and writing reviews about their public issues. His reviews are regularly published online and in news papers.

(Dilip Davda -SEBI registered Research Analyst-Mumbai,

Registration no. INH000003127 (Perpetual)

Email id: ).

Narayana Hrudayalaya IPO FAQs

  1. 1. Why Narayana Hrudayalaya IPO?

    The initial public offer (IPO) of Narayana Hrudayalaya Ltd offers an early investment opportunity in Narayana Hrudayalaya Ltd. A stock market investor can buy Narayana Hrudayalaya IPO shares by applying in IPO before Narayana Hrudayalaya Ltd shares get listed at the stock exchanges. An investor could invest in Narayana Hrudayalaya IPO for short term listing gain or a long term.

  2. 2. How is Narayana Hrudayalaya IPO?

    Read the Narayana Hrudayalaya IPO recommendations by the leading analyst and leading stock brokers.

  3. 3. Narayana Hrudayalaya IPO what should investors do?

    Narayana Hrudayalaya IPO offers an opportunity to buy IPO shares before they get listed at the stock exchanges. Read the Narayana Hrudayalaya IPO Notes, Analysis and Recommendations by leading stock brokerage firms and experts in the above answer.

  4. 4. Is Narayana Hrudayalaya IPO good?

    Our recommendation for Narayana Hrudayalaya IPO is to subscribe.

  5. 5. Is Narayana Hrudayalaya IPO worth Investing?

    As per the analysis by our lead analyst Mr. Dilip Davda, we suggest you to subscribe to the Narayana Hrudayalaya IPO.

  6. 6. When will Narayana Hrudayalaya IPO allotment status?

    The Narayana Hrudayalaya IPO allotment status will be available on or around [.]. The allotted shares will be credited in demat account by [.]. Visit Narayana Hrudayalaya IPO allotment status to check.

  7. 7. When will Narayana Hrudayalaya IPO list?

    The Narayana Hrudayalaya IPO will list on Wednesday, January 6, 2016, at BSE, NSE.